Nanoliposomal irinotecan plus fluorouracil and folinic acid in irinotecan-pretreated vs. -naive pancreatic cancer patients: A retrospective cohort study

被引：0
|
作者：
Schoenlein, M. [1 ]
Stein, A. [1 ,2 ]
Tintelnot, J. [1 ]
Nilsson, S. [1 ]
Reichelt, R. [3 ]
Borchardt, J. [3 ]
Schnell, R. [4 ]
Goekkurt, E. [1 ,2 ]
Bokemeyer, C. [1 ]
Sinn, M. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin Onkol Hamatol & Knochenmarktr, Abt Pneumol, Hamburg, Germany
[2] Hematol Oncol Practice Hamburg HOPE, Hamburg, Germany
[3] Onkotrakt AG, Hamburg, Germany
[4] Pioh Koln Nord Studien GbR, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep601
引用
收藏
页码：224 / 225
页数：2
相关论文
共 50 条
  • [1] Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer
    Rehman, Sana Saif Ur
    Lim, Kian
    Wang-Gillam, Andrea
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (05) : 485 - 492
  • [2] Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
    Park, Se Jun
    Kim, Hyunho
    Shin, Kabsoo
    Hong, Tae Ho
    Suh, Ja Hee
    Lee, Myung Ah
    BMC CANCER, 2021, 21 (01)
  • [3] Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
    Se Jun Park
    Hyunho Kim
    Kabsoo Shin
    Tae Ho Hong
    Ja Hee Suh
    Myung Ah Lee
    BMC Cancer, 21
  • [4] A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
    Kodama, Tomoko
    Imajima, Takashi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Kawahira, Masahiro
    Nakazawa, Junichi
    Hori, Takeshi
    Shibuki, Taro
    Arima, Shiho
    Ido, Akio
    Miwa, Keisuke
    Okabe, Yoshinobu
    Koga, Futa
    Ueda, Yujiro
    Kubotsu, Yoshihito
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Nishikawa, Kazuo
    Komori, Azusa
    Otsu, Satoshi
    Hosokawa, Ayumu
    Sakai, Tatsunori
    Sakai, Kenji
    Oda, Hisanobu
    Kawahira, Machiko
    Arita, Shuji
    Honda, Takuya
    Taguchi, Hiroki
    Tsuneyoshi, Kengo
    Kawaguchi, Yasunori
    Fujita, Toshihiro
    Sakae, Takahiro
    Shirakawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [5] Impact of biliary drainage for pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil and folinic acid
    Nishikawa, Kazuo
    Kubotsu, Yoshihito
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Ueda, Yujiro
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Hosokawa, Ayumu
    Sakai, Tatsunori
    Oda, Hisanobu
    Arita, Shuji
    Kawahira, Machiko
    Shiraawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    ANNALS OF ONCOLOGY, 2023, 34 : S1400 - S1400
  • [6] Efficacy and safety of nanoliposomal irinotecan plus fluorouracil and folinic acid after irinotecan-based chemotherapy in patients with advanced pancreatic cancer: Results of the retrospective part of the NAPOLEON-2 study.
    Kawaguchi, Yasunori
    Aikawa, Tomomi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Ueda, Yujiro
    Kubotsu, Yoshihito
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Nishikawa, Kazuo
    Hosokawa, Ayumu
    Oda, Hisanobu
    Sakai, Tatsunori
    Shirakawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 705 - 705
  • [7] Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
    Takeshi Kawakami
    Akiko Todaka
    Kotoe Oshima
    Kunihiro Fushiki
    Satoshi Hamauchi
    Takahiro Tsushima
    Tomoya Yokota
    Yusuke Onozawa
    Hirofumi Yasui
    Kentaro Yamazaki
    BMC Cancer, 23
  • [8] Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
    Kawakami, Takeshi
    Todaka, Akiko
    Oshima, Kotoe
    Fushiki, Kunihiro
    Hamauchi, Satoshi
    Tsushima, Takahiro
    Yokota, Tomoya
    Onozawa, Yusuke
    Yasui, Hirofumi
    Yamazaki, Kentaro
    BMC CANCER, 2023, 23 (01)
  • [9] Real-world evidence of nanoliposomal irinotecan and fluorouracil with folinic acid in patients with unresectable or recurrent pancreatic cancer: Final results of a multicenter observational study
    Shinohara, Yudai
    Shirakawa, Tsuyoshi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shimokawa, Hozumi
    Nakazawa, Junichi
    Koga, Futa
    Oda, Hisanobu
    Takeshita, Shigeyuki
    Arima, Shiho
    Arita, Shuji
    Kawaguchi, Yasunori
    Nishikawa, Kazuo
    Taguchi, Hiroki
    Jikuya, Kenichi
    Sakai, Tatsunori
    Ueda, Yujiro
    Sakae, Takahiro
    Mizuta, Toshihiko
    Mitsugi, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 721 - 721
  • [10] Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
    Bockorny, Bruno
    Macarulla, Teresa
    Semenisty, Valerya
    Borazanci, Erkut
    Feliu, Jaime
    Ponz-Sarvise, Mariano
    Abad, David Gutierrez
    Oberstein, Paul
    Alistar, Angela
    Munoz, Andres
    Geva, Ravit
    Guillen-Ponce, Carmen
    Fernandez, Mercedes Salgado
    Peled, Amnon
    Chaney, Marya
    Gliko-Kabir, Irit
    Shemesh-Darvish, Liron
    Ickowicz, Debby
    Sorani, Ella
    Kadosh, Shaul
    Vainstein-Haras, Abi
    Hidalgo, Manuel
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 5020 - 5027
12345